Menetrier's disease. A diagnostic and therapeutic challenge / Enfermedad de Menetrier. Un desafío diagnóstico y terapéutico

Abstract We present a rare case of hypertrophic gastropathy associated with protein loss. A 35-year-old man was hospitalized for bowel habit changes, abdominal pain, generalized edema and symptomatic anemia. Pertinent laboratory findings included iron deficiency anemia (Hb 6.7g/dl, ferritin 5 ng/ml) and marked hypoalbuminemia (albumin 2.5 g/dl). Endoscopic biopsy samples of giant gastric folds observed along the greater gastric curvature revealed foveolar hyperplasia and significant parietal cell loss. Endoscopic ultrasonography showed gastric parietal thickening with preserved architecture and normal gastric wall layers. Menetrier disease was diagnosed and the patient treated with cetuximab, a monoclonal antibody that inhibits ligand binding of trans forming growth factor alpha (TGFa), preventing gastric mucosa cell proliferation. After twelve months of treatment, the patient referred symptoms improvement, and gastric biopsy levels of the proliferation marker protein Ki-67 had decreased.

Resumen Presentamos un caso infrecuente de gastropatía hipertrófica asociada a pérdida de proteínas. Un hombre de 35 años fue hos pitalizado por cambios en los hábitos intestinales, dolor abdominal, edema generalizado y anemia sintomática. Los hallazgos de laboratorio pertinentes incluyeron anemia ferropénica (Hb 6.7 g/dl, ferritina 5 ng/ml) e hipoal buminemia marcada (albúmina 2.5 g/dl). Las muestras de biopsia endoscópica de pliegues gástricos gigantes observados a lo largo de la curvatura mayor gástrica revelaron hiperplasia foveolar y pérdida significativa de células parietales. La ecografía endoscópica mostró engrosamiento parietal gástrico con arquitectura conservada y capas de pared gástrica normales. Se diagnosticó enfermedad de Menetrier y se trató al paciente con cetuximab, un anticuerpo monoclonal que inhibe la unión del ligando del factor de crecimiento transformante alfa (TGFa), evitando la proliferación de células de la mucosa gástrica. Después de doce meses de tratamiento, el paciente refirió mejoría de los síntomas y los niveles de la proteína marcadora de proliferación Ki-67 en biopsia gástrica habían disminuido.

Primary gastric rupture in 20 horses from Midwestern Brazil: case report / Ruptura gástrica primária em 20 equinos no Centro-Oeste do Brasil: relato de caso

An 11-year (2007-2018) survey of epidemiological, clinical and pathological findings of horses with primary gastric rupture (PGR) was conducted. Twenty horses presented PGR, nine (45%) horses were clinically evaluated, eleven (55%) were sent dead, and all animals were necropsied. PGR contributed to a prevalence of 0.31% (9/2,868) of all equid attendances, 1.83% (9/491) of colic cases, and 4.1% (20/487) of all equid necropsies. Highly fermentable feed (n=7), gastric impaction (n=4), and perforating gastric ulcer (n=1) were the main causes of PGR; whilst eight horses presented idiopathic gastric rupture. Clinically evaluated horses were tachycardic, tachypneic, febrile, dehydrated, with increased abdominal tension, abnormal mucous membranes and reduced to absent intestinal borborygmi. Improper dietary management, such as the ingestion of low-quality roughage and highly fermentable feedstuffs were detected as the main factors associated with PGR in Midwestern Brazil. It is important to raise awareness in horse owners about proper feed management to minimize PGR.(AU)

Foi realizado um levantamento de 11 anos (2007-2018) dos achados epidemiológicos, clínicos e patológicos de equinos com ruptura gástrica primária (RGP). Vinte equinos apresentaram RGP, dos quais nove (45%) foram avaliados clinicamente e 11 (55%) foram enviados mortos, sendo todos os animais necropsiados. A RGP contribuiu com prevalência de 0,31% de todos os atendimentos de equídeos (9/2.868), 1,83% (9/491) dos casos de cólica, e 4,1% (20/487) das necropsias em equídeos. Alimentos altamente fermentáveis (n=7), compactação gástrica (n=4) e perfuração de úlcera gástrica (n=1) foram as principais causas de RGP, enquanto oito equinos tiveram ruptura gástrica idiopática. Os equinos avaliados clinicamente apresentaram-se taquicárdicos, taquipneicos, febris, desidratados, com mucosas anormais, aumento da tensão abdominal e motilidade intestinal reduzida. O manejo inadequado da dieta, como a ingestão de forragens de baixa qualidade e alimentos altamente fermentáveis, foi o principal fator de risco associado à RGP no Centro-Oeste do Brasil. É importante aumentar a conscientização dos proprietários de equinos sobre o manejo alimentar adequado para minimizar a RGP.(AU)

Carvedilol as primary prophylaxis for gastric variceal bleeding in portal hypertension model in rats / Carvedilol como profilaxia de sangramento em varizes gástricas em modelo de hipertensão portal em ratos

ABSTRACT Background: Portal hypertension (PH) can be measured indirectly through a hepatic vein pressure gradient greater than 5 mmHg. Cirrhosis is the leading cause for PH and can present as complications ascites, hepatic dysfunction, renal dysfunction, and esophagogastric varices, characterizing gastropathy. Aim: To evaluate the use of carvedilol as primary prophylaxis in the development of collateral circulation in rats submitted to the partial portal vein ligament (PPVL) model. Method: This is a combined qualitative and quantitative experimental study in which 32 Wistar rats were divided into four groups (8 animals in each): group I - cirrhosis + carvedilol (PPVL + C); group II - cirrhosis + vehicle (PPVL); group III - control + carvedilol (SO-sham-operated + C); group IV - control + vehicle (SO-sham-operated). After seven days of the surgical procedure (PPVL or sham), carvedilol (10 mg/kg) or vehicle (1 mL normal saline) were administered to the respective groups daily for seven days. Results: The histological analysis showed no hepatic alteration in any group and a decrease in edema and vasodilatation in the PPVL + C group. The laboratory evaluation of liver function did not show a statistically significant change between the groups. Conclusion: Carvedilol was shown to have a positive effect on gastric varices without significant adverse effects.

RESUMO Racional: A hipertensão portal (HP), medida indiretamente através do gradiente pressórico da veia hepática >5 mmHg, tem como principal causa etiológica a cirrose. Possui como complicações a ascite, disfunção hepática, disfunção renal e varizes esofagogástricas, que caracterizam o quadro de gastropatia. Objetivo: Avaliar o uso do carvedilol como profilaxia primária no desenvolvimento da circulação colateral em ratos submetidos ao modelo de ligadura parcial de veia porta (LPVP). Método: Estudo experimental qualitativo e quantitativo no qual foram utilizados 32 ratos Wistar, divididos em quatro grupos (n=8): grupo I - cirrose + carvedilol (LPVP+C); grupo II - cirrose + veículo (LPVP); grupo III - controle + carvedilol (SO - sham-operated+C); grupo IV - controle + veículo (SO - sham-operated). Após transcorridos sete dias do procedimento cirúrgico, foi administrado carvedilol (10 mg/kg) e veículo (1mL) para os respectivos grupos por sete dias consecutivos. Resultados: A análise histológica não mostrou alteração hepática em nenhum grupo e diminuição de edema e vasodilatação no grupo LPVP+C. A avaliação laboratorial da função hepática não mostrou alteração com significância estatística entre os grupos. Conclusão: Carvedilol mostrou ser fármaco com efeito positivo no sangramento das varizes gástricas e sem efeitos adversos significantes.

Gastropatía hiperplásica de tipo foveolar con Coinfección por Helicobacter pylori / Hyperplastic Gastropathy of the Foveolar Type with Helicobacter Pylori Coinfection

La Gastropatía hiperplásica de tipo foveolar o Enfermedad de Ménétrier es una gastropatía hipertrófica premaligna rara. Se caracteriza por un engrosamiento de los pliegues gástricos, secundario a una hiperplasia de las células mucosas foveolares frecuentemente asociada con pérdida de proteínas entéricas e hipoalbuminemia y síntomas tracto gastrointestinal superior como dolor epigástrico, malestar, náuseas y vómitos. Se ha relacionado con infecciones en la mayoría de los casos publicados, Citomegalovirus (CMV) y Helicobacter pylori (Hp). Se presenta el caso de adolescente con antecedente de epilepsia refractaria, quien ingresa por status convulsivo y durante hospitalización presenta sangrado digestivo alto con compromiso hemodinámico. Diagnosticándose enfermedad de Ménétrier por hallazgos endoscópicos y biopsia. Realizamos revisión de la literatura

Ménétrier's disease is a rare premalignant hypertrophic gastropathy. It is characterized by a thickening of the gastric folds, secondary to a hyperplasia of the foveolar mucosal cells, frequently associated with loss of enteric proteins and hypoalbuminemia and upper gastrointestinal tract symptoms such as epigastric pain, malaise, nausea and vomiting. It has been associated with infections in most of the published cases, Cytomegalovirus (CMV) and Helicobacter pylori (Hp).We present the case of a teenager with a history of refractory epilepsy, who is admitted due to convulsive status and during hospitalization he presents with high digestive bleeding with hemodynamic compromise. Diagnosing Ménétrier's disease by endoscopic findings and biopsy. We review the literature

Enfermedad de Ménétrier en pacientes pediátricos secundaria a una infección por citomegalovirus: Presentación de dos casos clínicos en un centro de alta complejidad / Ménétrier's disease in pediatric patients secondary to cytomegalovirus infection: Presentation of two clinical cases in a high complexity center

La enfermedad de Ménétrier es una gastroenteropatía perdedora de proteínas. Definida como una entidad rara y de causa desconocida, la mayoría de los casos reportados la han asociado a infecciones virales. En los pacientes pediátricos, presenta un comienzo agudo con un curso benigno y autolimitado. Se caracteriza por tener pliegues gástricos engrosados que, generalmente, involucran el cuerpo y el fundus gástrico, asociados a hipoalbuminemia, debido a la pérdida de proteína sérica a través de la mucosa. A continuación, se exponen dos casos clínicos de síndrome de Ménétrier infantil asociado a infección por citomegalovirus.

Ménétrier's disease is a protein losing gastroenteropathy. Defined as a rare entity with an unknown cause, most of the reported cases have been associated with viral infections. In pediatric patients, it is characterized by an acute onset with a benign and self-limiting course. It is characterized by thickened gastric folds that generally involve the body and the gastric fundus, associated with hypoalbuminemia due to the loss of serum protein through the mucosa. The following are two clinical cases of infant Ménétrier syndrome associated with cytomegalovirus infection.

Enfermedad de Ménétrier en niños: reporte de dos casos / Two cases of Menétrier's disease in children

Resumen Se presentan 2 casos de enfermedad de Ménétrier (EM) remitidos a nuestra institución por síndrome edematoso. Esta enfermedad de poca prevalencia es una gastropatía hipertrófica perdedora de proteínas que en la mayoría de los casos es de causa desconocida, aunque se ha asociado con procesos infecciosos. Se caracteriza por edema, hipoproteinemia, hipoalbuminemia y, en la infancia, es de carácter benigno y autolimitado.

Abstract We present two cases of Menétrier's Disease (MS) referred to our institution due to edema. The prevalence of this disease is low. It is a hypertrophic gastropathy which causes loss of proteins and which has unknown causes in the majority of cases although it has been associated with infectious processes. It is characterized by edema, hypoproteinemia, hypoalbuminemia. In childhood it is benign and self-limited.

Bioequivalencia clínica de dos marcas de esomeprazol administradas en pacientes con ulcus gastroduodenal / Clinical bioequivalence of 2 brands of esomeprazol administered in patients with gastroduodenal ulcus

Los inhibidores de bomba de protones son usados en el tratamiento de la gastropatía ácido-péptica. Objetivo: comparar la eficacia de dos marcas de esomeprazol en el tratamiento de gastropatía ácido-péptica, la evolución de síntomas y su tolerancia. Materiales y Métodos: Se incluyeron pacientes de ambos sexos, con edades entre 18-60 años, con o sin Helicobacter pylori, que en la gastroscopia presentaron una o más erosiones o úlceras ≥ 5 mm y < 25 mm en su diámetro mayor. Se distribuyeron aleatoriamente a recibir una de las marcas, 40 mg/día, oral, durante 4 semanas. Al final fueron evaluados con endoscopia, interrogatorio de efectos adversos y laboratorio, comparando tasa de curación y evolución de la endoscopia. Se evaluó la tasa de respondedores por disminución del score de síntomas y la tolerancia mediante interrogatorio de efectos adversos y pruebas de laboratorio. Resultados: Ingresaron 34 pacientes, analizando los resultados de 30. En ambos grupos observamos mejoría en la endoscopia (curación y/o mejoría). El score de síntomas mejoró en ambos grupos, con significancia intragrupo pero no intergrupal. Los efectos adversos no fueron significativos. Conclusiones: Observamos mejoría en los criterios de endoscopia, y en el score de síntomas, en ambos grupos.

Introduction: Proton pump inhibitors are used in the treatment of acid-peptic gastropathy. Objective: to compare the efficacy of two brands of esomeprazole in the treatment of acid-peptic gastropathy, the evolution of symptoms and their tolerance. Materials and methods: Patients of both sexes, aged 18-60 years, with or without Helicobacter pylori, who had one or more erosions or ulcers ≥ 5 mm and <25 mm in their largest diameter, in gastroscopy, were included. They were randomized to receive one of the brands, 40 mg / day, orally, for 4 weeks. At the end, they were evaluated with endoscopy, adverse event questioning and laboratory tests, comparing cure rate and evolution of endoscopy. We evaluated the rate of responders according to decreased symptom score, and tolerance through questioning of adverse effects and laboratory tests. Results: Thirty-four patients were enrolled, analyzing the results of 30 patients. In both groups we observed improvement in endoscopy (healing and / or improvement). The score of symptoms improved in both groups, with intragroup but not intergroup significance. Adverse events were not significant. Conclusions: Thirty-four patients were enrolled, analyzing the results of 30 patients. In both groups we observed improvement in endoscopy (healing and / or improvement). The score of symptoms improved in both groups, with intragroup but not intergroup significance. Adverse events were not significant.

Severe hypoproteinemia as a harbinger of Ménétrier's disease in autoimmune pancreatitis / Hipoproteinemia grave como indicador de doença de Ménétrier na pancreatite autoimune

Summary Ménétrier's disease is an extremely rare disease of unknown etiology causing gastric mucosal hypertrophy and protein-losing gastropathy. Rare cases of this condition have been reported in patients with autoimmune diseases. However, to the best of our knowledge, Ménétrier's disease associated with autoimmune pancreatitis (AIP) has never been reported. We described a case of severe hypoproteinemia as a harbinger of Ménétrier's disease associated with AIP. The patient was successfully treated with octreotide and high-protein diet, which led to symptomatic remission and significant improvement in serum levels of albumin and recovery of the nutritional status. Thus, in AIP patients presenting with severe and persistent hypoproteinemia without apparent cause, clinicians need to consider Ménétrier's disease in the differential diagnosis. In this setting, endoscopic evaluation with histological examination of gastric biopsy material, including a full-thickness mucosal biopsy of involved mucosa, may be helpful in promptly establishing the diagnosis and allowing appropriate and timely therapy.

Resumo A doença de Ménétrier é uma condição extremamente rara, de etiologia desconhecida, caracterizada por hipertrofia da mucosa gástrica e gastropatia perdedora de proteína. Casos raros dessa patologia têm sido relatados em pacientes com doenças autoimunes. Até o momento, desconhecemos qualquer relato dessa doença associada à pancreatite autoimune (PAI). Descrevemos um caso de hipoproteinemia grave como indicador de doença de Ménétrier associada à PAI. O paciente foi tratado de forma satisfatória com octreotide e dieta hiperproteica, alcançando remissão sintomática, melhora significativa das concentrações de albumina e recuperação do estado nutricional. Portanto, em pacientes com PAI e hipoproteinemia grave e persistente, deve-se considerar a doença de Ménétrier como um diagnóstico diferencial. Nesses casos, a avaliação endoscópica com biópsia gástrica, incluindo biópsia de toda a espessura da mucosa, pode ser útil no estabelecimento do diagnóstico e do pronto início da terapêutica.

Supervivencia del paciente cirrótico con gastropatía portal hipertensiva / Survival of the Cirrhotic Patient with Hypertensive Portal Gastropathy

Introducción: la gastropatía portal hipertensiva constituye una complicación de la hipertensión portal que ocurre en pacientes cirróticos. Objetivo: determinar la probabilidad de supervivencia en un grupo de pacientes cirróticos con gastropatía portal hipertensiva. Métodos: seguimiento longitudinal, prospectivo, para estudiar la supervivencia de 34 pacientes con cirrosis hepática atendidos en el servicio de Gastroenterología del Hospital Militar Central Dr. Luis Díaz Soto desde octubre de 2012 hasta octubre del 2015. Se construyeron las curvas de sobrevida total y por estratos, según clasificación de Child-Pugh-Turcotte, etiología de la cirrosis, gravedad de la gastropatía y ocurrencia de sangrado agudo durante el período de observación. Se utilizó para ello el método de Kaplan-Meier y la comparación de las curvas por el logaritmo de rangos. Resultados: se apreció una probabilidad de supervivencia global de 94,1 por ciento a los dos meses y 61,7 por ciento a los 30 meses. La media de la supervivencia para pacientes con gastropatía leve y grave fue de 29,1 y 29,7 meses, respectivamente; esta fue de 28,3 meses para casos con cirrosis por virus C y de 30,1 meses para los de otras etiologías. Hubo predominio de casos en estadios de Child A (41,2 percent) y B (47,1 percent), con una media de supervivencia de 33,5 y 30,1 meses; para los del Child C (12 por ciento) fue de 12 meses; (p= 0,05). De los pacientes, el 35,3 por ciento de los casos sangraron, con una media de supervivencia de 25,5 meses inferior respecto a los que no sangraron (p= 0,35). Conclusiones: la presencia de gastropatía portal hipertensiva se relaciona con una mayor probabilidad de fallecer cuando hay un mayor deterioro de la función hepática o ha ocurrido un sangrado agudo, a partir de los 30 meses de haberse realizado su diagnóstico(AU)

Introduction: Hypertensive portal gastropathy is a complication of portal hypertension that occurs in cirrhotic patients. Objective: Determine the probability of survival in a group of cirrhotic patients with hypertensive portal gastropathy. Methods: a longitudinal, prospective follow-up was conducted to study the survival of thirty four (34) patients with liver cirrhosis and they were treated at the Gastroenterology Service of Dr. Luis Díaz Soto Central Military Hospital from October 2012 to October 2015. Full-length and strata survival curves were constructed, according to Child-Pugh-Turcotte classification, as well as etiology of cirrhosis, severity of gastropathy, and occurrence of acute bleeding during the observation period. Kaplan-Meier method was used and the comparison of the curves by the logarithm of ranges. Results: A global survival probability of 94.1 was observed at two months and 61.7 percent at 30 months. The mean survival for patients with mild and severe gastropathy was 29.1 and 29.7 months, respectively; this was 28.3 months for cases with C virus cirrhosis and 30.1 months for those of other etiologies. There were predominant cases in Child A (41.2 percent) and B (47.1 percent), with an average survival of 33.5 and 30.1 months; For Child C (12 percent) was 12 months; (P = 0.05). 35.3 percent of the cases bled, with an average survival of 25.5 months lower than those who did not bleed (p = 0.35). Conclusions: The presence of hypertensive portal gastropathy is associated with a greater probability of dying when there is a greater deterioration of the liver function or acute bleeding has occurred, as of 30 months after having been diagnosed(AU)

Caracterización clínica de pacientes cirróticos con gastropatía portal hipertensiva / Clinical Characterization of Cirrhotic Patients with Hypertensive Portal Gastropathy

Introducción: la gastropatía portal hipertensiva (GPH) constituye una complicación de la hipertensión portal de relevancia clínica, que aparece en pacientes con cirrosis hepática. Objetivo: caracterizar los diferentes tipos de gastropatía portal hipertensiva (GPH) según la presencia de manifestaciones de hipertensión portal, el estado de la función hepática y la ocurrencia de eventos de sangrado digestivo. Método: estudio descriptivo, de corte transversal que incluyó 46 pacientes con diagnóstico de cirrosis y evidencia endoscópica de gastropatía portal hipertensiva (GPH), atendidos entre 2011-2013 en el servicio de Gastroenterología del Hospital Militar Central Dr. Luis Díaz Soto. Se clasificaron según su forma leve o grave y se hicieron comparaciones entre ambos grupos. Resultados: el 78,2 por ciento de los pacientes presentó una gastropatía leve y la localización más frecuente resultó ser el fondo gástrico (78,2 por ciento). Todos los casos con la forma grave fueron hombres (p=0,008). Entre los que tuvieron una gastropatía grave, predominaron los que tuvieron un mayor diámetro de la porta (18,3 mm vs 13,5 mm, p=0,001) y del bazo (137,4mm vs130,03 mm, (p=0,0002), así como los que también tenían várices esofágicas (100 por ciento, p=0,007), por lo que el sangrado agudo también fue más frecuente entre ellos (60 por ciento, p=0,01). No se manifestaron diferencias con los parámetros hematológicos de hipertensión portal ni con los grados de función hepática, aun cuando el 63 por ciento de los pacientes se encontró en los grupos B y C de la clasificación de Child-Pughs-Turcotte. Conclusiones: la forma grave de la gastropatía portal hipertensiva (GPH) es la menos frecuente, pero se acompaña de alteraciones clínicas, humorales e imaginológicas relevantes, que requieren una atención personalizada para este tipo de enfermos(AU)

Introduction: Hypertensive portal gastropathy (HPG) is a complication of portal hypertension of clinical relevance, which appears in patients with liver cirrhosis. Objective: Characterize the different types of hypertensive portal gastropathy (HPG) according to the presence of manifestations of portal hypertension, the state of liver function and the occurrence of digestive bleeding events. Method: A descriptive, cross-sectional study was conducted in 46 patients diagnosed with cirrhosis and endoscopic evidence of portal hypertensive gastropathy (HPG), treated from 2011 to 2013 in the Gastroenterology Department of Dr. Luis Díaz Soto Central Military Hospital. They were classified according to mild or severe form and comparisons were made between both groups. Results: 78.2 percent of the patients presented mild gastropathy and the most frequent location was the gastric fundus (78.2 percent). All cases with the severe form were men (p = 0.008). Among those who had severe gastropathy, those with larger diameter of the portal (18.3 mm vs 13.5 mm, p = 0.001) and spleen (137.4 mm vs 130.03 mm, p = 0, 0002), as well as those who also had esophageal varices (100 percent, p = 0.007), so that acute bleeding was also more frequent among them (60 percent, p = 0.01). Hematologic factors of portal hypertension or with degrees of liver function, although 63 percent of patients were found in groups B and C of the Child-Pughs-Turcotte classification. Conclusions: The severe form of hypertensive portal gastropathy (GPH) is the least frequent, but it is accompanied by relevant clinical, humoral and imaging alterations, which require a personalized attention for this type of patients(AU)

Gastropatía hipertrófica perdedora de proteínas: enfermedad de Ménétrier: caso clínico / Hypertrophic protein-losing gastropathy: Ménétrier disease: a clinical case

Introduction: Ménétrier disease is a rare disorder characterized by gastric foveolar hyperplasia associated with secondary protein loss. In children, this condition is presented as an edematous syndrome without renal or hepatic impairment and differs from the adult form by the constant presence of edema and spontaneous remission. It has been related to infections in most published cases, especially to Cytomegalovirus (CMV) and Helicobacter pylori (H. pylori). Objective: To present a pediatric case of Ménétrier disease and endoscopic imaging obtained during the evolution of the patient. Case report: A five year old preschooler who presented a generalized edema, abdominal pain and malaise. After ruling out renal and hepatic pathologies, an upper endoscopy revealed a severe compromise of the gastric mucosa. Urease test for H. pylori and IgG test for CMV resulted positive. Albumin and H2 receptor antagonists were administered. The evolution was favorable and the patient was discharged after 14 days; 8 month follow-up endoscopy showed no abnormalities. Conclusion: The medical profile and endoscopy are enough evidence to suggest the diagnosis of hypertrophic protein-losing gastropathy. Further studies need to be developed that include a considerable number of patients to assess their association with CMV or H. pylori infections, as these viruses are very common in our population.

Introducción: La enfermedad de Ménétrier es una entidad clínica rara, de etiología desconocida, que se caracteriza por hiperplasia foveolar gástrica asociada a pérdida secundaria de proteínas. En niños, se presenta como un síndrome edematoso sin compromiso renal ni hepático y difiere de la forma adulta por la presencia constante de edema y la remisión espontánea En la mayoría de los casos publicados se la relaciona a infecciones, en especial a Cytomegalovirus (CMV) y Helicobacter pylori (Hp). Objetivo: Presentar un caso pediátrico de Enfermedad de Ménétrier y las imágenes endoscópicas que se obtuvieron durante su evolución. Caso clínico: Preescolar de 5 años que consultó por edema generalizado, dolor abdominal y compromiso del estado general. Habiéndose descartado patología renal y hepática se solicitó una endoscopía digestiva alta que reveló un severo compromiso de la mucosa gástrica. Test de ureasa para Hp e IgG para CMV positivos. Se administró albúmina y antagonistas de receptores H2. La evolución fue favorable con alta al día 14 y endoscopía normal a los 8 meses de seguimiento. Conclusión: El cuadro clínico y la endoscopía son suficientes para plantear el diagnóstico de "Gastropatía hipertrófica perdedora de proteínas". Es necesario desarrollar estudios con un número considerable de pacientes para evaluar su asociación con infección por CMV o Hp, considerando además que estas infecciones son muy frecuentes en nuestra población.

Gastritis y gastropatías: [revisión] / Gastritis and gastropathies: [review]

Se hace una revisión de los diferentes tipos de gastritis, incluyendo cuadros en los que el edema y eritema puede semejar el cuadro, pero sin la típica reacción inflamatoria que denominamos gastropatías. Se hace una descripción de diversos aspectos epidemiológicos, etiológicos, etiopatogénicos; se desarrolla diversas clasificaciones propuestas y se describe los métodos diagnósticos, tratamientos recomendados y el pronóstico de esta molestia tan común.

A review of the different types of gastritis, including features in which the edema and erythema can resemble the picture, but without the typical inflammatory reaction that is called gastropathy. A description of various epidemiological, aetiological, pathogenetic, are proposed. The review describes the diagnoses and treatment recommendations and prognosis of this common disorder.

Comparación de cápsula endoscópica esofágica y endoscopia digestiva superior para el diagnóstico de varices esofagicas en Maracaibo Venezuela: reporte preliminar / Comparison between esophageal capsule endoscopy and esophagogastroduodenoscopy for the diagnosis of esophageal varices in Maracaibo Venezuela: preliminary report

La cápsula endoscópica (CE) para intestino delgado inició una revolución tecnológica que se extendió a esófago buscando alternativas para la endoscopia digestiva superior (EDS), “gold standard” en estudio de várices esofágicas (VE) pero invasivas y desagradables sin sedación. Antes de EDS con sedación moderada, 9 pacientes cirróticos de consulta de Hepatología, 6 para seguimiento VE (66.6%) y 3 para despistaje (33.4%) ingirieron PillCam™ESO (Given Imaging). Endoscopista entrenado en CE (ciego a hallazgos EDS pero no a historia del paciente) leyó dos veces los resultados. Se evaluó en imágenes CE y EDS: Presencia-tamaño de várices esofágicas, Riesgo de sangrado, Presencia-grado de Gastropatía Portal Hipertensiva (GPH), várices gástricas. Se aplicaron dos cuestionarios de satisfacción: pre y post procedimiento. CE demostró 88,8% de sensibilidad para determinar tamaño y riesgo de sangrado y 66.6% para GPH. Un hallazgo visto solo por CE, incluyó una várice gástrica. 88% de los pacientes manifestó mayor ansiedad-incomodidad con EDS, prefiriendo CE para futuros procedimientos. A pesar de la eficacia, comodidad y utilidad de CE para seleccionar pacientes para EDS, no creemos que pueda sustituir totalmente a EDS por imposibilidad de tratamiento y costo. Los resultados son prometedores, ampliando la muestra tendremos conclusiones más sólidas...

Endoscopic Capsule (EC) for small bowl is a gastrointestinal breakthrough which extended to esophagus searching for alternatives to esophagogastroduodenoscopy (EGD); “gold standard” for esophageal varices (EV) study (but invasive and uncomfortable without sedation). We report our preliminary EC results in Maracaibo. Before EGD with moderated sedation, 9 cirrhotic patients, 6 (55%) for surveillance and 3 for variceal screening, underwent EC PillCam™ESO (Given Imaging). Endoscopist with EC training (blinded to EGD founds but not to patient’s history) read twice the results. EC and EGD images were evaluated for EV size, bleeding risk, portal hypertensive gastropathy (PHG) grade, gastric varices and other founds. Two satisfaction questionnaires were applied (pre and post procedure). EC showed 88.8% sensibility in determining EV size and bleeding risk and 66.6% sensitivity for PHG. A gastric varice was seen only by EC. 88% of the patients were more anxious and uncomfortable with EGD preferring EC for future procedures. Though EC is efficient, comfortable and useful in deciding which patients would benefi t from EGD we don’t think it will totally replace EGD, due to its cost and impossibility for treatment. Results are promising although bigger samples are necessary for solid conclusions...

Linitis plástica: presentación como gastropatía hipertrófica / Linitis plastica: presentation as hypertrophic gastropathy

Presentamos el caso de una mujer de 78 años, que presentaba importante pérdida de peso y su endoscopia digestiva alta demostró pliegues gástricos gigantes. Se realizaron biopsias con asa de polipectomía en busca del diagnóstico y posible enfermedad neoplásica. La histopatología documentó gastropatía hipertrófica. La ecoendoscopia gástrica demostró una pared muy gruesa y aunque se sospechó neoplasia no podía ser conclusiva, solamente después de realizada la gastrectomía total se diagnosticó linitis plástica. Presentamos la revisión de pliegues gástricos gigantes así como las causas y clasificación de la gastropatía hipertrófica.

We present 78 year old Colombian lady who had lost weight and had giant gastric folds in her upper endoscopy. Intensive work up was done including extra large biopsies done with polipectomy snares. The pathology diagnosed hypertrophic gastropathy. Endoscopic ultrasound of the stomach diagnosed a very thick gastric wall. Only after total gastrectomy was done, Linitis Plastica was diagnosed. We review giant gastric folds as well as causes and classification of the hypertrophic gastropathy.